Ascent works with emerging biopharma to prospectively integrate Asia, particularly Japan and China, into global drug development thus enabling rapid market entry, increasing global product value, and enhancing the value of licensing partnerships. Ascent can provide either targeted, short-term consulting in support of rapid out-licensing deals, or comprehensive, long-term regulatory and clinical development services in support of ambitious strategic/commercial goals in Asia.